share_log

8-K: Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

8-K: Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

8-K：Cingulate公布2024年第二季度财务业绩，并提供已实现的重大里程碑的最新发展情况
美股SEC公告 ·  2024/08/13 20:02

Moomoo AI 已提取核心信息

On August 13, 2024, Cingulate Inc., a biopharmaceutical company, announced its financial results for the second quarter ended June 30, 2024, and provided updates on its clinical and business developments. The company reported significant progress with its lead product candidate, CTx-1301, for the treatment of ADHD, including FDA clearance to file for marketing approval and the completion of registration batches, which are essential for a New Drug Application (NDA) submission targeted for the first half of 2025. Cingulate also completed a payer study to assess the market potential for CTx-1301 and raised $1.6 million through a warrant inducement. Additionally, the company executed a one-for-twelve reverse stock split to comply with Nasdaq's Minimum Bid Price requirement. As of June 30, 2024, Cingulate had cash and cash equivalents of $0.4 million and total liabilities of $1.9 million, a decrease from the previous year. The company's net loss for the quarter was $3.2 million, a decrease from the $6.6 million loss reported for the same period in 2023, primarily due to reduced R&D and G&A expenses.
On August 13, 2024, Cingulate Inc., a biopharmaceutical company, announced its financial results for the second quarter ended June 30, 2024, and provided updates on its clinical and business developments. The company reported significant progress with its lead product candidate, CTx-1301, for the treatment of ADHD, including FDA clearance to file for marketing approval and the completion of registration batches, which are essential for a New Drug Application (NDA) submission targeted for the first half of 2025. Cingulate also completed a payer study to assess the market potential for CTx-1301 and raised $1.6 million through a warrant inducement. Additionally, the company executed a one-for-twelve reverse stock split to comply with Nasdaq's Minimum Bid Price requirement. As of June 30, 2024, Cingulate had cash and cash equivalents of $0.4 million and total liabilities of $1.9 million, a decrease from the previous year. The company's net loss for the quarter was $3.2 million, a decrease from the $6.6 million loss reported for the same period in 2023, primarily due to reduced R&D and G&A expenses.
2024年8月13日，生物制药公司Cingulate Inc.宣布了截至2024年6月30日第二季度的财务结果，并就其临床和业务发展提供了更新信息。该公司在其ADHD治疗的领先产品候选药CTx-1301方面取得了重大进展，包括FDA清除申请营销批准和提交新药申请（NDA）所必需的注册批次的完成，拟定于2025年上半年申请批准。Cingulate还完成了一项支付者研究，以评估CTx-1301的市场潜力，并通过认股诱因筹集了160万美元。此外，该公司执行了一项1:12的股票拆分，以符合纳斯达克最低标准要求。截至2024年6月30日，Cingulate的现金及现金等价物为40万美元，总负债为190万美元，低于去年同期。该公司本季度的净亏损为320万美元，较2023年同期报告的660万美元减少，主要是由于减少了研发和一般管理开支。
2024年8月13日，生物制药公司Cingulate Inc.宣布了截至2024年6月30日第二季度的财务结果，并就其临床和业务发展提供了更新信息。该公司在其ADHD治疗的领先产品候选药CTx-1301方面取得了重大进展，包括FDA清除申请营销批准和提交新药申请（NDA）所必需的注册批次的完成，拟定于2025年上半年申请批准。Cingulate还完成了一项支付者研究，以评估CTx-1301的市场潜力，并通过认股诱因筹集了160万美元。此外，该公司执行了一项1:12的股票拆分，以符合纳斯达克最低标准要求。截至2024年6月30日，Cingulate的现金及现金等价物为40万美元，总负债为190万美元，低于去年同期。该公司本季度的净亏损为320万美元，较2023年同期报告的660万美元减少，主要是由于减少了研发和一般管理开支。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间